You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Patent: 9,045,547

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,045,547

Title:	Methods of using antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
Abstract:	Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
Inventor(s):	Jackson; Simon Mark (San Carlos, CA), Walker; Nigel Pelham Clinton (Burlingame, CA), Piper; Derek Evan (Santa Clara, CA), Shan; Bei (Redwood City, CA), Shen; Wenyan (Palo Alto, CA), Chan; Joyce Chi Yee (San Francisco, CA), King; Chadwick Terence (North Vancouver, CA), Ketchem; Randal Robert (Snohomish, WA), Mehlin; Christopher (Seattle, WA), Carabeo; Teresa Arazas (New York, NY)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	13/251,909
Patent Claims:	see list of patent claims
Scope and claims summary:	Elucidating the Scope and Claims of United States Patent 9045547: An Analysis of Therapeutic Peptides United States Patent 9045547, titled "Intracellular and/or extracellular delivery system for therapeutic peptide compositions," was granted to pharmaceutical company Genta Inc. The patented technology focuses on a novel delivery system for therapeutic peptides. This article delves into the patent's scope and claims to decipher its significance. Background and Problem Statement The patent's background emphasizes the importance of delivering therapeutic peptides across cell membranes to achieve optimal therapeutic effects. Current methods including cell-penetrating peptides (CPPs) are limited by non-specific cell targeting, toxicity, and instability. Claims and Delivery System The patent's claims are centered around a novel delivery system featuring a polycationic compound, a peptide sequence, and a polyanionic molecule. This unique combination is designed to facilitate intracellular and/or extracellular delivery of therapeutic peptides. The delivery system boasts improved potency, reduced toxicity, and increased stability compared to existing CPPs. Scope and Implications The patented technology extends to various applications, including gene therapy, cancer treatment, and other diseases amenable to peptide-based therapies. The scope encompasses different modes of delivery, including systemic, topical, and parenteral administration. This comprehensive approach enables the targeted delivery of therapeutic peptides to specific cells, tissues, and organs. Claims Listing Selected claims from United States Patent 9045547 highlight the delivery system's significance: Claims 1 and 15: Method of delivering at least one therapeutic peptide across a cell membrane using a polycationic compound, peptide sequence, and polyanionic molecule. Claims 13 and 25: Peptide composite comprising a polycationic compound, peptide sequence, and polyanionic molecule for intracellular and/or extracellular delivery of therapeutic peptides. Claims 23 and 29: Use of the peptide composite in a systemic, topical, or parenteral mode of administration. Assessment and Outlook United States Patent 9045547 presents a promising delivery system for therapeutic peptides, offering improved potency, reduced toxicity, and enhanced stability. As the pharmaceutical industry continues to evolve, this technology may unlock novel treatments for a range of diseases. Patent protection for such innovative delivery systems serves as a safeguard for companies seeking to commercialize groundbreaking advancements in biotechnology and medicine.

Details for Patent 9,045,547

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	REPATHA	evolocumab	Injection	125522	August 27, 2015	9,045,547	2027-08-23
Amgen Inc.	REPATHA	evolocumab	Injection	125522	July 08, 2016	9,045,547	2027-08-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 9,045,547

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2009026558	⤷ Subscribe
United States of America	9920134	⤷ Subscribe
United States of America	9493576	⤷ Subscribe
United States of America	9056915	⤷ Subscribe
United States of America	8981064	⤷ Subscribe
United States of America	8889834	⤷ Subscribe
United States of America	8883983	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.